NO20010213L - 5-tia-<omega>-substituerte fenyl-prostaglandin-E-derivater, fremgangsmÕte ved fremstilling av slike samt medikamenter omfattende slike som aktiv bestanddel - Google Patents
5-tia-<omega>-substituerte fenyl-prostaglandin-E-derivater, fremgangsmÕte ved fremstilling av slike samt medikamenter omfattende slike som aktiv bestanddelInfo
- Publication number
- NO20010213L NO20010213L NO20010213A NO20010213A NO20010213L NO 20010213 L NO20010213 L NO 20010213L NO 20010213 A NO20010213 A NO 20010213A NO 20010213 A NO20010213 A NO 20010213A NO 20010213 L NO20010213 L NO 20010213L
- Authority
- NO
- Norway
- Prior art keywords
- thia
- prostaglandin
- omega
- disease
- syndrome
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000011580 syndromic disease Diseases 0.000 abstract 2
- 230000009885 systemic effect Effects 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010050685 Cytokine storm Diseases 0.000 abstract 1
- 208000013558 Developmental Bone disease Diseases 0.000 abstract 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000011200 Kawasaki disease Diseases 0.000 abstract 1
- 208000004987 Macrophage activation syndrome Diseases 0.000 abstract 1
- 208000034486 Multi-organ failure Diseases 0.000 abstract 1
- 208000010718 Multiple Organ Failure Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010072610 Skeletal dysplasia Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 231100000354 acute hepatitis Toxicity 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 206010052015 cytokine release syndrome Diseases 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 abstract 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract 1
- 208000020408 systemic-onset juvenile idiopathic arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP20075298 | 1998-07-15 | ||
| PCT/JP1999/003798 WO2000003980A1 (fr) | 1998-07-15 | 1999-07-14 | DERIVES DE PHENYL-POSTAGLANDINE E 5-THIA-φ-SUBSTITUES, PROCEDE DE PRODUCTION DESDITS DERIVES ET MEDICAMENTS CONTENANT LESDITS DERIVES EN TANT QUE PRINCIPE ACTIF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20010213D0 NO20010213D0 (no) | 2001-01-12 |
| NO20010213L true NO20010213L (no) | 2001-03-15 |
| NO327781B1 NO327781B1 (no) | 2009-09-21 |
Family
ID=16429595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20010213A NO327781B1 (no) | 1998-07-15 | 2001-01-12 | 5-tia-ω-substituerte fenyl-prostaglandin E-derivater |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6462081B1 (no) |
| EP (1) | EP1097922B1 (no) |
| JP (1) | JP3174563B2 (no) |
| KR (1) | KR100598660B1 (no) |
| CN (1) | CN1173945C (no) |
| AT (1) | ATE291013T1 (no) |
| AU (1) | AU763668B2 (no) |
| BR (1) | BR9912813B1 (no) |
| CA (1) | CA2336952C (no) |
| DE (1) | DE69924258T2 (no) |
| DK (1) | DK1097922T3 (no) |
| ES (1) | ES2239448T3 (no) |
| HU (1) | HUP0204170A3 (no) |
| NO (1) | NO327781B1 (no) |
| NZ (1) | NZ509293A (no) |
| PT (1) | PT1097922E (no) |
| RU (1) | RU2220135C2 (no) |
| TR (1) | TR200100623T2 (no) |
| TW (1) | TWI249520B (no) |
| WO (1) | WO2000003980A1 (no) |
| ZA (1) | ZA200100295B (no) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL350917A1 (en) | 1999-03-05 | 2003-02-10 | Procter & Gamble | C16 unsaturated fp-selective prostaglandins analogs |
| CA2303060A1 (en) * | 1999-04-14 | 2000-10-14 | United States Gear Corporation | Towed vehicle brake controller |
| AU7557600A (en) * | 1999-10-07 | 2001-05-10 | Ono Pharmaceutical Co. Ltd. | Erection insufficiency remedies |
| TWI247606B (en) | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
| KR20020067594A (ko) * | 2000-01-05 | 2002-08-22 | 오노 야꾸힝 고교 가부시키가이샤 | 5-티아-ω-치환 페닐-프로스타글란딘 Ｅ-알콜, 이들의제조 방법 및 이들을 유효 성분으로서 함유하는 약제 |
| DK1132086T3 (da) | 2000-01-31 | 2006-08-28 | Pfizer Prod Inc | Anvendelse af prostaglandin (PGE2) selektive receptor 4 (EP4) agonister til behandling af akut og kronisk nyresvigt |
| US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US6586462B2 (en) * | 2000-10-20 | 2003-07-01 | Allergan, Inc. | ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists |
| GB0030541D0 (en) * | 2000-12-14 | 2001-01-31 | Glaxo Group Ltd | Medical uses |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| ATE366571T1 (de) * | 2001-07-16 | 2007-08-15 | Hoffmann La Roche | 2 pyrrolidon-derivate als prostanoid-agonisten |
| CN1893977B (zh) * | 2001-07-23 | 2012-12-05 | 小野药品工业株式会社 | 以ep4激动剂为活性成分的治疗与骨质损失有关的疾病的药物 |
| MXPA04000757A (es) * | 2001-07-23 | 2004-07-08 | Ono Pharmaceutical Co | Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo. |
| CA2457468A1 (en) * | 2001-08-09 | 2003-02-27 | Ono Pharmaceutical Co., Ltd. | Carboxylic acid derivatives and pharmaceutical agent comprising the same as active ingredient |
| JP2003078830A (ja) * | 2001-09-03 | 2003-03-14 | Sony Corp | デジタル放送受信装置および通信情報伝送方法 |
| WO2003030911A1 (en) * | 2001-10-08 | 2003-04-17 | Medical Research Council | Use of prostaglandin e synthase inhibitors, or ep2 or ep4 receptor antagonists, in the treatment of a pathological condition of the uterus |
| WO2003037373A1 (en) * | 2001-10-31 | 2003-05-08 | Medical Research Council | Use of an ep2 or ep4 receptor antagonist and/or a cox-1 inhibitor for treating cervical cancer |
| WO2003037348A1 (en) * | 2001-10-31 | 2003-05-08 | Medical Research Council | Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorrhagia |
| EP1452178A1 (en) * | 2001-11-12 | 2004-09-01 | Ono Pharmaceutical Co., Ltd. | Persistent filmy preparation for topical administration containing prostaglandin derivative |
| CA2479222A1 (en) * | 2002-03-18 | 2003-09-25 | Pfizer Products Inc. | Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension |
| GB0208785D0 (en) * | 2002-04-17 | 2002-05-29 | Medical Res Council | Treatment methtods |
| AU2003233729B2 (en) * | 2002-06-06 | 2007-10-04 | Merck Frosst Canada Ltd | 1,5-distributed pyrrolid-2-one derivatives for use as EP4 receptor agonists in the treatment of eye diseases such as glaucoma |
| JP3678366B2 (ja) * | 2002-08-09 | 2005-08-03 | 大正製薬株式会社 | 止痒剤 |
| US7737182B2 (en) | 2002-08-09 | 2010-06-15 | Taisho Pharmaceutical Co., Ltd. | Pharmaceuticals for xerosis |
| AU2003272963A1 (en) * | 2002-10-10 | 2004-05-04 | Ono Pharmaceutical Co., Ltd. | Endogenous repair factor production promoters |
| JP4477504B2 (ja) * | 2002-11-13 | 2010-06-09 | 大正製薬株式会社 | 鎮痒剤 |
| MXPA05008307A (es) * | 2003-02-07 | 2005-09-20 | Ono Pharmaceutical Co | Compuestos de acidos carboxilicos. |
| US7855226B2 (en) * | 2003-02-11 | 2010-12-21 | Allergan, Inc. | Treatment of inflammatory bowel disease |
| CA2513652A1 (en) | 2003-03-03 | 2004-09-16 | Applied Research Systems Ars Holding N.V. | G-lactam derivatives as prostaglandin agonists |
| US7465755B2 (en) | 2003-07-18 | 2008-12-16 | Laboratoires Serono Sa | Hydrazide derivatives as prostaglandin receptors modulators |
| CN1946391A (zh) * | 2004-04-20 | 2007-04-11 | 辉瑞产品公司 | 包含α－2－δ配体的组合 |
| US7858610B2 (en) * | 2004-08-10 | 2010-12-28 | Ono Pharmaceutical Co., Ltd. | Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist |
| WO2006016695A1 (ja) * | 2004-08-10 | 2006-02-16 | Ono Pharmaceutical Co., Ltd. | Ｅｐ４アゴニストを含有してなる高カリウム血症の予防および／または治療剤 |
| WO2006047476A2 (en) * | 2004-10-26 | 2006-05-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| JPWO2006075690A1 (ja) * | 2005-01-14 | 2008-06-12 | 小野薬品工業株式会社 | 安定な医薬組成物 |
| JPWO2006118173A1 (ja) | 2005-04-28 | 2008-12-18 | 小野薬品工業株式会社 | 経皮吸収製剤 |
| GB0524103D0 (en) | 2005-11-26 | 2006-01-04 | Medical Res Council | Healing |
| US7511168B2 (en) | 2006-01-18 | 2009-03-31 | Shih-Yi Wei | Processes and intermediates for the preparations of prostaglandins |
| UY30121A1 (es) | 2006-02-03 | 2007-08-31 | Glaxo Group Ltd | Nuevos compuestos |
| KR20090075864A (ko) | 2006-10-26 | 2009-07-09 | 오노 야꾸힝 고교 가부시키가이샤 | 첨부제 |
| AU2007331471C1 (en) | 2006-12-15 | 2013-07-25 | Glaxo Group Limited | Benzamide derivatives as EP4 receptor agonists |
| US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| AU2008246579A1 (en) | 2007-05-08 | 2008-11-13 | National University Corporation, Hamamatsu University School Of Medicine | Cytotoxic T cell activator comprising EP4 agonist |
| GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
| US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP2349242B1 (en) | 2008-10-29 | 2018-12-05 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
| WO2010077101A2 (ko) | 2008-12-30 | 2010-07-08 | 조선대학교산학협력단 | 신규한 티아졸리딘디온 유도체 및 그의 용도 |
| CA2929545C (en) | 2009-05-01 | 2019-04-09 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| JP2013536183A (ja) * | 2010-07-30 | 2013-09-19 | アラーガン インコーポレイテッド | 皮膚修復のための化合物及び方法 |
| US8697057B2 (en) | 2010-08-19 | 2014-04-15 | Allergan, Inc. | Compositions and soft tissue replacement methods |
| US20120142684A1 (en) * | 2010-12-02 | 2012-06-07 | Allergan, Inc. | Compounds and methods for skin repair |
| EP2675491A2 (en) | 2011-02-17 | 2013-12-25 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2678022A2 (en) | 2011-02-23 | 2014-01-01 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2814510A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013123275A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013123274A1 (en) | 2012-02-16 | 2013-08-22 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| EP2814482A1 (en) | 2012-02-16 | 2014-12-24 | Allergan, Inc. | Compositions and improved soft tissue replacement methods |
| WO2013167582A1 (en) | 2012-05-09 | 2013-11-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for prevention or treatment of chronic obstructive pulmonary disease |
| NZ704178A (en) | 2012-07-19 | 2017-08-25 | Cayman Chemical Co Inc | Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
| ES2733998T3 (es) | 2012-10-29 | 2019-12-03 | Cardio Incorporated | Agente terapéutico específico de enfermedad pulmonar |
| EP3461484B9 (en) | 2013-03-15 | 2021-06-09 | Aerie Pharmaceuticals, Inc. | Dimesylate salts of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl, their combinations with prostaglandins and the use thereof in the treatment of ocular disorders |
| WO2014144610A1 (en) | 2013-03-15 | 2014-09-18 | Cayman Chemical Company, Inc. | Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions |
| CN105392505A (zh) | 2013-07-19 | 2016-03-09 | 开曼化学股份有限公司 | 用于促进骨生长的方法、系统和组合物 |
| US9968716B2 (en) | 2013-10-15 | 2018-05-15 | Ono Pharmaceutical Co., Ltd. | Drug-eluting stent graft |
| US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
| BR112019003945A2 (pt) | 2016-08-31 | 2019-05-21 | Aerie Pharmaceuticals, Inc. | composições oftálmicas |
| CN110506037A (zh) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | 芳基环丙基-氨基-异喹啉酰胺化合物 |
| AU2019337703B2 (en) | 2018-09-14 | 2023-02-02 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58198466A (ja) | 1982-05-12 | 1983-11-18 | Teijin Ltd | ５−チアプロスタグランジン類およびその製造法 |
| JPH072711B2 (ja) | 1986-09-24 | 1995-01-18 | 帝人株式会社 | プロスタグランジンｅ▲下１▼誘導体の製造法 |
| EP0386901A1 (en) | 1989-02-20 | 1990-09-12 | Ono Pharmaceutical Co., Ltd. | Novel 5-hetero-6-oxo-PGE derivatives |
| JPH03223244A (ja) * | 1989-02-20 | 1991-10-02 | Ono Pharmaceut Co Ltd | ５―ヘテロ―６―オキソ―ｐｇｅ誘導体、それらの製造方法およびそれらを含有する薬剤 |
| JP3579448B2 (ja) | 1993-12-29 | 2004-10-20 | 大正製薬株式会社 | プロスタグランジン誘導体、その塩およびその使用 |
-
1999
- 1999-07-09 TW TW088111637A patent/TWI249520B/zh not_active IP Right Cessation
- 1999-07-14 EP EP99929831A patent/EP1097922B1/en not_active Expired - Lifetime
- 1999-07-14 RU RU2001101470/04A patent/RU2220135C2/ru not_active IP Right Cessation
- 1999-07-14 CN CNB998097039A patent/CN1173945C/zh not_active Expired - Fee Related
- 1999-07-14 JP JP2000560089A patent/JP3174563B2/ja not_active Expired - Fee Related
- 1999-07-14 ES ES99929831T patent/ES2239448T3/es not_active Expired - Lifetime
- 1999-07-14 PT PT99929831T patent/PT1097922E/pt unknown
- 1999-07-14 DK DK99929831T patent/DK1097922T3/da active
- 1999-07-14 WO PCT/JP1999/003798 patent/WO2000003980A1/ja not_active Application Discontinuation
- 1999-07-14 AU AU46518/99A patent/AU763668B2/en not_active Ceased
- 1999-07-14 BR BRPI9912813-6A patent/BR9912813B1/pt not_active IP Right Cessation
- 1999-07-14 AT AT99929831T patent/ATE291013T1/de active
- 1999-07-14 NZ NZ509293A patent/NZ509293A/en not_active IP Right Cessation
- 1999-07-14 TR TR2001/00623T patent/TR200100623T2/xx unknown
- 1999-07-14 HU HU0204170A patent/HUP0204170A3/hu unknown
- 1999-07-14 CA CA002336952A patent/CA2336952C/en not_active Expired - Fee Related
- 1999-07-14 US US09/720,675 patent/US6462081B1/en not_active Expired - Fee Related
- 1999-07-14 DE DE69924258T patent/DE69924258T2/de not_active Expired - Lifetime
- 1999-07-14 KR KR1020017000093A patent/KR100598660B1/ko not_active IP Right Cessation
-
2001
- 2001-01-10 ZA ZA200100295A patent/ZA200100295B/en unknown
- 2001-01-12 NO NO20010213A patent/NO327781B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PT1097922E (pt) | 2005-06-30 |
| DE69924258D1 (de) | 2005-04-21 |
| HUP0204170A3 (en) | 2005-03-29 |
| ZA200100295B (en) | 2002-07-10 |
| WO2000003980A1 (fr) | 2000-01-27 |
| EP1097922A4 (en) | 2003-02-12 |
| CN1312796A (zh) | 2001-09-12 |
| TR200100623T2 (tr) | 2001-06-21 |
| HUP0204170A2 (hu) | 2003-04-28 |
| EP1097922A1 (en) | 2001-05-09 |
| ES2239448T3 (es) | 2005-09-16 |
| AU763668B2 (en) | 2003-07-31 |
| ATE291013T1 (de) | 2005-04-15 |
| AU4651899A (en) | 2000-02-07 |
| RU2220135C2 (ru) | 2003-12-27 |
| KR20010053386A (ko) | 2001-06-25 |
| DK1097922T3 (da) | 2005-05-30 |
| NO20010213D0 (no) | 2001-01-12 |
| BR9912813A (pt) | 2001-05-02 |
| BR9912813B1 (pt) | 2010-11-30 |
| DE69924258T2 (de) | 2006-01-26 |
| JP3174563B2 (ja) | 2001-06-11 |
| US6462081B1 (en) | 2002-10-08 |
| NO327781B1 (no) | 2009-09-21 |
| KR100598660B1 (ko) | 2006-07-13 |
| CA2336952A1 (en) | 2000-01-27 |
| CA2336952C (en) | 2009-09-15 |
| TWI249520B (en) | 2006-02-21 |
| EP1097922B1 (en) | 2005-03-16 |
| NZ509293A (en) | 2003-05-30 |
| CN1173945C (zh) | 2004-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20010213D0 (no) | 5-tia-<omega>-substituerte fenyl-prostaglandin-E-derivater, fremgangsmåte ved fremstilling av slike samt medikamenter omfattende slike som aktiv bestanddel | |
| US5859021A (en) | Antiviral combinations | |
| BR0107964A (pt) | Derivados de nicotinamida benzofundida com heterociclica úteis como inibidores seletivos de isozimas pde4 | |
| JP2012513412A5 (no) | ||
| MA27431A1 (fr) | Derives de pyrimidinone utilises comme agents therapeutiques contre des processus inflammatoires ischemiques et de remodelage aigus et chroniques | |
| ATE205494T1 (de) | Pyridylfuran- und pyridylthiphenderivate und deren pharmazeutische verwendung | |
| JP2005519916A5 (no) | ||
| DE69818286D1 (de) | Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen | |
| KEATING | Antiviral agents | |
| CN109071473A (zh) | 新型抗病毒化合物 | |
| JP2002537258A5 (no) | ||
| DE68906609D1 (de) | Dopamin-vorlaeufer. | |
| CA2003289A1 (en) | Use of trifluoromethylphenyl-tetrahydropyridines for the preparation of pharmaceutical compositions useful for the treatment of anxiety and anxio-depressive disorders | |
| EP1258473A4 (en) | BENZOIC ACID DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL PRODUCT CONTAINING SUCH DERIVATIVES AS ACTIVE INGREDIENT | |
| Wiebe et al. | Concepts for the design of anti-HIV nucleoside prodrugs for treating cephalic HIV infection | |
| ES2215327T3 (es) | Composicion de medicamento inmunomodulador. | |
| Kerr et al. | Highly water-soluble lipophilic prodrugs of the anti-HIV nucleoside analog 2', 3'-dideoxycytidine and its 3'-fluoro derivative | |
| DK1064262T3 (da) | Substituerede isoindoloner og deres anvendelse som cycliske GMP-modulatorer i lægemidler | |
| Meier et al. | 5′, 5′‐di‐O‐nucleosyl‐O′‐benzylphosphotriesters as potential prodrugs of 3′‐azido‐2′, 3′‐dideoxythymidine‐5′‐monophosphate | |
| AU526978B2 (en) | Tetracyclic indole derivatives | |
| FI892685A0 (fi) | Menetelmä uusien, sytostaattisesti vaikuttavien antrasykliinijohdannaisten valmistamiseksi | |
| Khandazhinskaya et al. | 5′‐Phosphonate Derivatives of 2′, 3′‐Dideoxy‐3′‐Thiacytidine as New Anti‐HIV Prodrugs | |
| JPS6140206B2 (no) | ||
| ATE252089T1 (de) | Polyhydroxyalkylpyrazine derivate,deren herstellung und diese enthaltende arzneimitteln | |
| JPS6213325B2 (no) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |